

**Author Listing of Comprehensive Relationships With Industry for Transcatheter Therapies for Mitral Regurgitation: a Professional Society Overview from the ACCF, AATS, SCAI and STS**

<b>Committee Member</b>	<b>Employment</b>	<b>Consultant</b>	<b>Speaker's Bureau</b>	<b>Ownership/ Partnership/ Principal</b>	<b>Personal Research</b>	<b>Institutional, Organizational or Other Financial Benefit</b>	<b>Expert Witness</b>
Patrick T. O'Gara <i>Chair</i>	Brigham and Women's Hospital—Professor of Medicine; Harvard Medical School—Director, Clinical Cardiology	None	None	None	<ul style="list-style-type: none"> <li>• Lantheus Medical Imaging</li> <li>• National Institutes of Health*</li> </ul>	None	None
John H. Calhoun	University of Texas Health Science Center—Professor and Chair, CT Surgery Department	None	None	None	None	None	None
Marc R. Moon	Barnes-Jewish Hospital, Cardiothoracic Surgery, Washington Medical Center—Program Director, Professor of Surgery	None	None	None	None	<ul style="list-style-type: none"> <li>• Atricure†</li> <li>• Carbomedics†</li> <li>• Edwards Lifesciences†</li> </ul>	<ul style="list-style-type: none"> <li>• 2012 – Defendant, Aortic Rupture</li> </ul>
Carl L. Tommaso	NorthShore University HealthSystem, Evanston Hospital—Interventional Cardiologist	None	None	None	None	<ul style="list-style-type: none"> <li>• SCAI†</li> </ul>	<ul style="list-style-type: none"> <li>• 2004 – Defendant, Acute MI</li> <li>• 2006 – Defendant, Retained Wire</li> </ul>

This table represents all healthcare relationships of committee members with industry and other entities that were reported by authors, including those not deemed to be relevant to this document, at the time this document was under development. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of  $\geq 5\%$  of the voting stock or share of the business entity, or ownership of  $\geq \$10,000$  of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Please refer to <http://www.cardiosource.org/Science-And-Quality/Practice-Guidelines-and-Quality-Standards/Relationships-With-Industry-Policy.aspx> for definitions of disclosure categories or additional information about the ACCF Disclosure Policy for Writing Committees.

\*Significant relationship.

†No financial benefit.